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ABSTRACT

OBJECTIVE: To determine whether ERr 731 extract from the Rheum rhaponticum plant is
effective in relieving symptoms of menopausal symptoms in women aged 45 to 55 years of age
STUDY DESIGN: Review of all English language double blind randomized controlled trial
studies from 2006 to 2009.
DATA SOURCES: Randomized, controlled, double-blind, placebo controlled clinical trials
comparing extract ERr731 to placebo were found in MEDLINE, OVID, and COCHRANE
databases.
OUTCOMES MEASURED: All three trials measured Menopause Rating Scale II. Also
determined in the review is the severity and number of hot flushes, and also a change in the
quality of life. Results for anxiety used the HAMA scale and results for changes in quality of
life and well being were assessed on the Menopause specific Quality Of Life, Women’s Health
Questionnaire, diary reports and the psychological general well being index.
RESULTS: All three trials showed results demonstrating significant results using extract
ERr731 to decrease severity and number of hot flashes, increase the quality of life and also
decrease overall menopause symptoms in women aged 45 to 55 years old. Participants in Heger
et al reported adverse events but no serious adverse events.
CONCLUSIONS: The results of the three trials show that extract ERr 731 is effective in
reducing symptoms and severity of symptoms in menopause compared to placebo. The extract
however, has not been evaluated by many other studies or the FDA therefore true side effects
and risks are not determined.
KEY WORDS: Menopause, climacteric, hot flushes.
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INTRODUCTION
Menopause is the transition period that occurs in all women usually between the ages of
45 and 55 when menstruation eventually stops. It is a natural biological termination of the ability
to reproduce in the female population where eggs are no longer released from the ovaries. Some
of the most common symptoms resulting include hot flushes and mood swings which women
search for treatments to find relief. Current treatments are available but aren’t always effective or
they have significant side effects. This paper evaluated randomized controlled double blind
clinical trials comparing ERr731 extract to placebo in alleviating symptoms of menopause.
Relieving menopausal symptoms is common to encounter in all fields of PA practice. The
majority of women experience some symptoms within their lifetime at an average age onset at
51. About 85% of women have symptoms for 1 year, 25% for 5 years and about 15% of women
have symptoms for 15 years or more (Manson , 2010). In the transition from perimenopause to
menopause, symptoms can disrupt the quality of life. About one-third of women will consult a
doctor annually because of menopausal symptoms but definite cost is unknown (Gunthrie 2003).
After the age of 35, ovarian mass and fertility decline. The process of depletion of primary
follicles begins before birth and continues steadily until menopause. In perimenopause, intervals
between menstrual cycles shorten by about 3 days due to an accelerated follicular phase.
Follicle-stimulating hormone (FSH) levels rise, from altered folliculogenesis and reduced inhibin
secretion. The consistently high FSH and low estradiol levels cause irregular hormone levels.
During the transition into menopause, estradiol levels fall and estrone levels are preserved. FSH
levels increase more than luteinizing hormone (LH) levels, due to the loss of inhibin, and
estrogen feedback. The change in hormones and age give rise to vasomotor symptoms (hot
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flushes), menstrual cycle alterations, vaginal dryness and atrophy, sleep disturbances, mood
changes, skin hair and nail changes, and osteoporosis.
Treatments for menopause symptoms include hormone replacement therapy. The
replacement of hormones can involve estrogen only, progestin only or a combination of both.
There are oral combinations including Prempro and Premphase, patch combinations including
Estraderm, Climara Pro or Combipatch. Other forms of hormone replacement include vaginal
suppositories, which are estrogen hormone only, including Estrace and Premarin. Other alternate
treatments include Selective Serotonin Reuptake Inhibitors (SSRI), soy, Black Cohosh, St.
John’s Wart, 1200mg Calcium per day, and 400-800mg Vitamin D per day.
The method of treatment being proposed is that hormone replacement therapy is effective
but has adverse side effects making them unsuitable for many patients. Some of the side effects
include an increased risk of blood clot formation, cancer (especially breast cancer),
cerebrovascular accidents and heart disease. The alternative treatments are not as affective and
also cause adverse reactions and drug interactions including headache, dizziness, nausea,
sedation, constipation, allergic reactions and drug interactions. One of the major side effects is
the interaction of St. John’s Wort and the possible adverse reaction with inducing metabolism of
P450 drugs. However, the extract ERr731 from the Rheum rhaponticum may provide
satisfactory reduction in symptoms without any serious adverse effects.
OBJECTIVE
The objective of this systematic review is to determine whether or not “Is extract ERr731
from the Rheum rhaponticum effective in relieving menopausal symptoms in women aged 45 to
55 years of age?” Although previous studies have shown some efficacy in hormone replacement
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therapy and other alternative treatments, extract ERr731 from the Rheum rhaponticum plant has
not previously been tested and thus efficacy of this extract is unknown.
METHODS
Each of the three studies selected for this review meet the following criteria: The
population included females aged 45-55 with climacteric complaints and a Menopause Rating
Scale II score of > 18 who have an irregular menstrual cycle lasting for the past 12 months
and/or their last menstruation was at least 3 months ago but no longer than 12 months ago.
Exclusion criteria includes women who have regular menstrual cycles 3 months prior, PAP
smear of class III/IV endometrial hyperplasia, concomitant medication that might impair the trial
results, abnormal endometrium and breast, presence of concomitant disease, alcohol, smoking,
caffeine, and a body mass index less than 18 kg/m2 or greater than 30 kg/m2. The intervention
used in the studies was 4mg tablets of ERr731 extract from the Rheum rhaponticum plant in
tablet form. The treatment groups were compared to control groups given a visually matched
placebo. The main outcomes which were measured in a prospective, randomized, double-blind
placebo controlled clinical study were anxiety, quality of life and hot flushes. All English
written articles were searched using key words like menopause, climacteric, and hot flushes on
OVID, Medline and Cochrane databases. Each article was selected based on patient oriented
evidence that matters (POEMS) and also were published in peer-reviewed journals between 1996
and the present. Table 1 includes the demographics of the 3 clinical trials which met the
previously listed inclusion criteria. Statistics reported include p values < 0.05 indicating clinical
significance.
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A.) Table 1 - Demographics & Characteristics of included studies
Characteristics of studies included in systematic review of the effectiveness of ERr731 extract
from the root of Rheum rhaponticum in the treatment of menopausal symptoms.
Study
Type
#
Age Inclusion Criteria Exclusion
W/ Interventions
yrs
Criteria
D
Heger
Multicenter 110 45- Women with
Regular
64 1 enteric
et al.
prospective
55
climacteric
menstrual cycles
coated tablet
doublecomplains
3 months prior.
of ERr731
blind,
Menopause
PAP smear of
extract daily
placebo
Rating Scale II
class III/IV,
for 12 weeks
controlled,
( MRS II) of more endometrial
RCT
than 22 points
hyperplasia,
concomitant
Kaszkin Multicenter 109 4564 Enteric
45
to
55
years
old
medications
that
- Bettag prospective
55
coated tablets
who have an
might impair the
2007
doubleof 250 mg of
irregular
trial results.
blind,
ERr731
menstrual cycle
placebo
lasting for the
controlled,
past 12 months
RCT
and/or their last
menstruation was
at least 3 but no
longer than 12
months ago.
Kaszkin Multicenter 112 45- Women aged 45
Abnormal
19 Enteric
- Bettag ,
55
to 55 years old
endometrium
coated tablets
2009
prospective
with irregular
and breast,
containing 4
, doublemenstruation
presence of
mg of Rheum
blind,
cycles during the concomitant
rhaponticum
placebo
past 12 months or diseases, use of
dry extract
controlled,
last menstrual
predefined
RCT
period > 3 but <
medications,
12 months ago.
pretreatment of
Menopausal
menopausal
Rating Scale total symptoms
score > 18 points alcohol, smoking
indicating
and caffeine, and
moderate to
a body mass
severe menstrual
index less than
symptoms.
18 kg/m2 or over
than 30 kg/m2
[*Ref = Reference number. See reference page for list of papers cited]
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OUTCOMES MEASURED
Outcomes were measured using patient completed severity score surveys or
questionnaires on anxiety, quality of life, or hot flushes. In the article by Heger, et al. the
outcomes were measured using a diary, MRSII, and the menopause specific quality of life
(MENQOL) score completed by the participants. Kaszkin-Bettag et. al (2007) use the
Hamilton Anxiety Scale (HAMA), Menopause Rating Scale II ( MRSII), the psychological
general well being index, and Women’s Health Questionaire (WHQ) all completed by the
participants to measure their outcomes. In the article by Kaszkin-Bettag et al. (2009) the
outcomes were measured using the MRS II and a diary completed by the participants also.
RESULTS
The randomized controlled trials selected are double blind, prospective clinical trials
analyzed with intention to treat and all participants in the trials who meet inclusion criteria
received the same ERr731 treatment or placebo, see table 1 for details. Some data from each
study is reported in dichotomus data yet other important data was unable to be converted into
dichotomous.
In Heger Et al, a total of 55 participated for the placebo group and 54 participants were
involved in the ERr731 treatment group. Only7 participants from the control trial and 39
participants from the ERr731 treatment group finished the experiment. Discontinuation in the
treatment group totaled 16. One for lack of efficacy, 3 for violation of the smoking ban, 3 for
adverse events, 2 for organizational reasons and 7 for other reasons not listed. In the placebo
group, a total of 48 discontinued the study. Thirty-one discontinued for lack of efficacy, 1 for
violation of the smoking ban, 1 for adverse events, and 16 for other reasons. The Heger et al
study measured menopausal symptoms throughout the studying using the Menopausal Rating
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Scale II, which includes 11 symptoms assessed on a 6-point rating scale from 0=not present to 5
being most severe and a maximum score of 55 {17 Heger,M. 2006;}. Table 2A shows results
from the MRSII scores. On day 0 the treatment and placebo group had similar scores on the
MRSII, 34.0+ 5.6 and 27.9+ 8.7 respectively. By the end of the study, there were only 46
participants in the ERr731 group but a significant decrease in the average MRSII score to 13.5 +
6.3 showing a reduction in about 20 points. The placebo group only had 12 participants who
completed the study who reported an average MRSII score of 27.9 + 8.7 {17 Heger,M. 2006;}.
Table 2B shows results from the MENQOL, the Menopause-specific quality of life. From the
participants’ diaries the MENQOL score was calculated on 4 domains: vasomotor,
psychological, physical and sexual. The total score in each domain ranges from 1 to 8 and a
lower score indicates a better quality of life. In table 2B, the average MENQOL score for each
group is listed on day 0 and day 84. Both groups had similar scores when beginning the
assessment, however, by day 84 the ERr731 score decreased more than the placebo group.
Seventeen adverse events occurred in 16 women during the study; events included back pain,
intercostals neuralgia, dizziness, viral infection of the upper respiratory tract, duodenal ulcer,
cardiomyopathy, dysuria, weight gain, endometrium dysplasia and uterofibroma {17 Heger,M.
2006;}. Table 2D shows results for the adverse events and no events were considered to be
related to the investigation medication {17 Heger,M. 2006;}.
Table 2 A. Heger et al.: Severity scores on the MRSII
Time Group
#
MRS II
95% CI
SS
Day ERr731 54 34.0 + 5.6 32.516P<
0
35.558
0.001
Placebo 55 32.6 + 4.8 31.32933.944
Day ERr731 46 13.5 + 6.3 11.621P<
84
15.379
0.0001
Placebo 12 27.9 + 8.7 22.38133.452

Table 2 B. Heger et al. reference #1:
Reduction in severity scores on the
Menopause-specific Quality of Life
Questionaire (MENQOL)
Time
Group
Total
SS
Day 0 ERr731
4.72
P<
0.05
Placebo
4.46
Day
ERr731
2.69
P<
84
0.05
Placebo
3.36
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Table 2 C. Heger et al. reference #1: Reduction in the number and severity of hot flushes during
the past 24 hours recorded in participant diaries. (p<0.0001).
Time
Group
Total hot flushes /day
Severity
Number of specific hot flushes
Baseline
ERr731 16.2 + 7.7
Slight
7.6 + 2.5
Day 0
n=44
Moderate 5.5 + 3.6
Severe
3.1 + 4.7
Placebo 14.8 + 6.9
Slight
7.4 + 4.3
n=46
Moderate 4.6 + 3.2
Severe
3.1 + 6.9
Decrease ERr731 -5.5 + 4.4
Slight
-0.2 + 2.8
in number n=43
Moderate -2.8 + 3.1
on Day 28
Severe
-2.6 + 4.6
Placebo 0.0 + 3.2
Slight
-0.6 + 2.8
n=42
Moderate 0.2 + 2.5
Severe
0.3 + 3.0

Table 2D. Heger et al. total adverse events.
Group
Participants with adverse events RR
RRI
ARI
NNH
ERr731 8/54= 0.1481 = 14.81%
1.02 =
0.0186 =
0.0027 =
370.3 = 370
102%
1.86%
0.27%
Placebo 8/55 = 0.1454 = 14.54%
In Kaszkin-Bettag et al, 2007, the study focused on decreasing anxiety and the well
being of women after the 84 day trial of ERr731 extract compared to the placebo. The Hamilton
Anxiety Scale was used to determine a baseline and change in anxiety symptoms. The rating
scale determines the severity of anxiety symptoms consisting of 14 items like muscle aches and
pains, depressed mood, fears, insomnia, and tension. Each of the categories are rated on a 0 (not
present) to 5 ( severe) {16 Kaszkin-Bettag,M. 2007;}. At baseline, day 0, the total HAMA score
was similar between both placebo and treatment group. The ERr731 groups’ score was 27.5 +
6.8 and the baseline score for the placebo group was 25.1 + 6.0. On day 84, the group treated
with ERr731 had an average score of 9.4 + 4.2. The placebo group’s HAMA average total at the
end of the trial decreased to 21.6 + 8.6. (See table 3a ) {16 Kaszkin-Bettag,M. 2007;}. Another
measurement to determine the success of ERr731 was the Psychological General Well-Being
Index. It is a self-administered quality of life assessment. Table 3C shows the results and
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changes in the index reported by participants. As referenced in the table, Day 0 scores were
“low spirits mostly” or “I have been up and down in spirits a lot”. On day 84, 59.3% of
participants reported being in good spirits mostly from the ERr731 treatment group compared to
7.3% of the placebo group {16 Kaszkin-Bettag,M. 2007;}. Kaszkin-Bettag et all 2006 also used
the MRSII to measure the changes in anxiety in particular for the study. Table 3D represents
differences in slight and severe anxiety at baseline and at the end of the trial. The percent of
severe anxiety in both treatment and placebo groups was more significant in number. The
participants that experienced severe anxiety was 48.1% in the treatment group and 45.5% in the
placebo group. At the end of the study, the percent of women with severe anxiety in the
treatment group was 1.9%, and in the placebo group it was 32.7% {16 Kaszkin-Bettag,M.2007;}.
Table 3A. Kaszkin-Bettag et al. 2007.
Changes in the HAMA total score in
women from the ERr731 and placebo
groups. (P<0.0001)
Time Group
#
HAMA total
score
Day ERr731 54 27.5 + 6.8
0
Placebo 55 25.1 + 6.0
Day ERr731 46 9.4 + 4.2
84
Placebo 12 21.6 + 8.6

Table 3B. Kaszkin-Bettag et al. 2007.
Women’s Health Questionnaire (WHQ)
result.
Time
Day 0
Day 84

Group
ERr731
Placebo
ERr731
Placebo

WHQ score
83.5+ 10.0
85.5 + 7.7
105.9 + 16.6
77.0 + 25.5

Table 3C. Kaszkin-Bettag et al 2007. Psychological General Well-Being Index results.
Time Group
Participants
Result
RR
RBI
ABI
NNT
Day ERr731 21/54 (38.9%) “Low spirits mostly” 1.78 0.784 = 0.171 = 5.85 =
0
78.4%
17.1%
6
Placebo 12/55 (21.8%)
ERr731 31/54 (57.4%) “ I have been up and 0.790 -0.267 = -0.153 = -6.54 =
-26.7%
-15.3%
-7
Placebo 40/55 (72.7%) down in spirits a lot”
Day ERr731 32/54 (59.3%) “In good spirits
8.12 7.12 =
0.52=
1.92 =
84
mostly”
712%
52%
2
Placebo 4/55 (7.3%)
Kaszkin-Bettag et al. 2009 measured a change in overall menopausal symptom change
through the MRS scale and also looked at number of hot flushes women experienced in a 24hour time span. Table 4A shows the change in MRS score from day 0 to 84 in the ERr731
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(decreased by 14.6 on the MRS scale) and also demonstrated the change in number of hot
flushes women experienced per day {14 Kaszkin-Bettag,M. 2009;}.
Table 3D Kaszkin-Bettag et al 2007 . Anxiety symptoms of the menopause rating scale II.
Time Group
Severity #
%
RR
RBI
ABI
NNT
Day ERr731 Slight
3/54
5.6
7.727
6.745
0.371
2.695
0
Placebo Slight
3/55
5.5
ERr731 Severe
26/54
48.1
1.057
0.057
0.026
38.46
Placebo Severe
25/55
45.5
Day ERr731 Slight
12/54
22.2
1.11
0.11
0.022
45.45
84
Placebo Slight
11/55
20.0
ERr731 Severe
1/54
1.9
0.058
-0.942
-0.308
3.25
Placebo Severe
18/55
32.7
Table 4A shows the change in MRS score from day 0 to 84 in the ERr731 (decreased by
14.6 + 5.1) and the placebo group (decreased by (2.9 + 4.3). Table 4B, displays the decrease in
average number of hot flashes experienced by women throughout the intervention {14 KaszkinBettag,M. 2009;}. Table 4C gives the evidence that a clinician needs to treat 28 women in order
to harm one more in the treatment group.
Table 4A Kaszkin-Bettag. Et al. 2009.
MRS total score changes from base
line to day 84.
Time
Group
MRS total
score
Day 0
ERr731 27.0 + 4.7
Placebo 27.0 + 5.3
Decrease in ERr731 -14.6 + 5.1
total score
Placebo -2.9 + 4.3
on Day 84
Table 4C. Adverse event reports.
Group
Number of patients with AEs
ERr 731
5/56 = 0.0892 = 8.92%
Placebo
3/56 = 0.0536 – 5.36%
DISCUSSION

Table 4B. Kaszkin-Bettag et al. 2009.
Number of hot flashes reported in
diaries by participants.
Time
Group
Number of hot
flushes
Day 0
Day 84

RRI
0.664 =
66.4%

ERr731
Placebo
ERr731

11.4 + 5.8
12.1 + 6.0
2.8 + 2.8

Placebo

11.4 + 6.8

ARI
0.0356 =
3.56%

NNH
28.0

The randomized controlled trials in this review of extract ERr 731 in the treatment of
menopausal symptoms showed that the medication can safely treat the symptoms and improve
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quality of life. The reduction of menopausal symptoms, especially anxiety and hot flushes, and
an increase in quality of life was consistently demonstrated within all 3 clinical trials. Since
there is numerous data collected, a reference for the abbreviation meanings is helpful to obtain
more information from the charts. Risk ratio (RR) is the ratio of the probability of developing an
outcome in a specified time among those who received the treatment compared with the
probability of developing the outcome among those who didn’t receive the treatment. Relative
risk increase (RRI) and absolute risk increase (ARI) are used to determine the increase risk of a
bad thing happening. Alternatively, relative benefit increase (RBI) and absolute benefit increase
(ABI) determine the probability of a good thing happening. Finally, the number needed to harm
(NNH) or number needed to treat determines how many people need to be treated in order to
have 1 increase in a bad event or 1 increase in a good event respectively. Heger et al. and
Kaszkin-Bettag 2009 reported adverse events. The calculations determined from Table 2D
demonstrate that for every 370 women who had the experimental treatment, there was 1 more
incidence of adverse reaction in the group that had a placebo, even though the adverse events
were not necessarily related to the treatment {17 Heger,M. 2006;}. . In Kaszkin-Bettag et al
2006, showed similar results for successful treatment. In reference to table 3c the number needed
to treat decreased from 6 to 2 by the end of the trial. Therefore, a clinician would need to treat
only 2 mothers to relieve menopausal symptoms, therefore increasing the quality of life. The
most impressive result from table 3D shows changes in anxiety, specifically by the end of the
trial, a clinician would need to treat 3.25 women in order to have one more decrease in severe
anxiety compared to baseline where 38.46 women needed treatment before there was one
reduction in severe anxiety. Even though the extract seems effective, it had not been evaluated
by the food and drug administration, it is only available online through one distributer. The
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limitations in the clinical trials include the discontinuation in treatment within both groups in all
three studies. In Heger et al, and Kaszkin-Bettag et all 2006, 39 women in the treatment group
and only 7 women in the control group completed the study. However, all participants, 54 from
treatment and 55 from control group were followed up in a 48 observational study. In KaszkinBettag et all 2009, 47 women in the treatment group and 46 women in the control group
completed the study as planned. With the participants who were lost, all were entered into a 52
week observational study for follow up.
CONCLUSION
The studies reviewed demonstrate that extract ERr 731 is effective in reducing
menopausal symptoms and increasing the quality of life for women suffering from symptoms.
However, there are not many trials with varying amounts of extract. In all 3 clinical trials
reviewed, 4mg tablets were used. Future studies should focus varying treatment dosages and
treatment start time to determine if symptoms could be prevented or present with minimal
severity. Table 1 shows the inclusion and exclusion criteria which is significant and challenging
for an entire population to follow. Future studies should have trials on women who do smoke,
drink, have dysplasia and other exclusion criteria that were listed to make sure that more women
could take the treatment and be successful rather than a small subset of women. Finally, the
studies reviewed for this paper were all completed in Germany, for completeness, a study should
be conducted in the United States to determine if the extract could reduce physical and mental
parameters of menopausal symptoms within a different culture.
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